Protocols

Limited clinical evidence available. The current literature on follistatin-344 dosing protocols is extremely sparse, with no standardized clinical protocols established through formal clinical trials.

Reported Usage Patterns

Based on limited case reports and observational studies:

High-dose administration has been associated with adverse effects, specifically central serous chorioretinopathy (fluid accumulation under the retina), though specific dosing amounts were not clearly documented in the available literature
Black market formulations have been detected and analyzed, indicating unregulated use, but without reliable dosing information
Most research has focused on detection methods and safety concerns rather than therapeutic protocols

Research Context

Preclinical studies in transgenic pigs showed increased skeletal muscle mass with follistatin-344 expression, but these involved genetic modification rather than exogenous administration
Pharmacokinetic studies of engineered variants exist but do not provide standard dosing recommendations for clinical use
No formal phase I, II, or III clinical trials were identified in the literature search

Safety Considerations

The available evidence indicates potential serious adverse effects with high-dose use, particularly ocular complications. The lack of regulatory approval and presence in black market preparations raises significant safety concerns about purity, potency, and appropriate dosing.

Medical Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. Follistatin-344 is not approved by regulatory agencies for therapeutic use. Any consideration of this compound should involve consultation with qualified healthcare providers who can assess individual medical circumstances and provide appropriate guidance based on current evidence and safety considerations.

Follistatin 344

Member access required